---

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2012

					(Rupees in '000')
S. No.	Particulars		Un -audited			Audited
			Quarter Ended			Year Ended
			30.06.2012	31.03.2012	30.06.2011	31.03.2012
PART - I
1	(a) Income from Operation
		Gross Sales	23,253	13,225	21,972	70,455
		Less: Excise Duty	1,547	1,509	797	4,435
	Net Sales		21,706	11,716	21,175	66,020
	(b) Other Operating  Income		-	-	-	-
	Total Income from Operation		21,706	11,716	21,175	66,020
2	Expenditure		-	-	-	-
	(a)	Consumption of Materials	5,984	6,761	6,237	24,418
	(b)	Purchase of Goods Traded	1,870	937	688	3,457
	(c)	(Increase)/Decrease in stock in trade	2,389	-5,021	4,426	-1,095
	(d)	Staff Cost	6,881	4,610	5,442	22,545
	(e)	Depreciation	653	666	644	2,599
	(f)	Other Expenditure	3,112	3,292	3,038	11,694
	Total Expenditure		20,889	11,245	20,475	63,618
3	Profit /Loss from Operation Before Other Income (1-2)		817	471	700	2,402
4	Other  Income /(Loss)		206	159	29	369
5	Profit /Loss before Interest & Exceptional items (3+4)		1,023	630	729	2,771
6	Interest		537	569	410	1,893
7	Profit /Loss  after Interest but before exceptional items (5-6)		486	61	319	878
8	Exceptional items		-	-	-	-
9	Profit /Loss before Tax (7-8)		486	61	319	878
10	Tax Expenses (Provision for Taxation):      Current tax		-	-	-	158
		Deffered tax	-	-	-	-384
11	Net Profit/Loss  after Tax (9-10)		486	61	319	1,104
12	Paid up Equity Share Capital (Face Value 10/- Per Share)		354,35	354,35	354,35	354,35
	[Net of allotment money in arrears]
13	Reserves Excluding Revaluation Reserves		-	-	-	7,630
14	Earning per share (EPS) before extraordinary item (not Annualised)		-	-	-	-
	Basic & Diluted		-	-	-	0.24
PART-II	A. PARTICULARS  OF SHAREHOLDING
1	Public Shareholding
	i)	Number of Shares	29,04,900	29,02,900	29,02,900	29,02,900
	ii)	Percentage of shareholding	63.55%	63.51%	63.51%	63.51%
2	Promoters and promoter group Shareholding
	a)	Pledged/Encumbered
	i)	Number of shares	-	-	-	-
	ii)	Percentage of shares (as a % of the total shareholding of	-	-	-	-
		promoter and promoter group)
	iii)	Percentage of shares (as a% of the total share capital of the company)	-	-	-	-
	b)	Non-encumbered
	i)	Number of Shares	16,66,100	1668100	1668100	1668100
	ii)	Percentage of shares (as a% of the total shareholding)	36.45%	36.49%	36.49%	36.49%
		of promoter and promoter group)
	iii)	Percentage of shares (as a % of the total share capital of the company)	100%	100%	100%	100%

 

	B. INVESTORS COMPLAINTS		3 Months ended 30.06.12
	Pending at Begining of the Quarter		NIL
	Received During the Quarter		NIL
	Disposed of During the Quarter		NIL
	Remaining at the end of the Quarter		NIL

 

NOTES :-

The above financial results have been taken on record at a meeting of Board of Directors held on  31.07.2012 The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable. Previous period figures have been regrouped wherever required.

 

	For and on behalf of the Board
	COLINZ LABORATORIES LIMITED
Mumbai	Dr. L. S. Mani
31.07.2012	Chairman & Managing Director.

                                                                                                                     

(Top)